Type 2 diabetic nephropathy (type 2 DN) patients traditionally develop significant proteinuria prior to the development of renal impairment. However, this clinical paradigm, based on observations prior to the widespread usage of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB), has recently been questioned. 2,303 patients enrolled in the Sulodexide Overt Nephropathy Study (OVERT) were analyzed. Prior therapy with ACEi and/or ARB at the time of screening was recorded in 951 patients. 22% of patients had significant renal impairment with a PCR at screening of <500 mg/g. Therapy with ACEi and/or ARB at the time of screening was recorded in 94%, where prior medication data was available. In patients with type 2 DN and advanced renal impairment, levels of proteinuria below that which traditionally defines overt diabetic nephropathy, are found in more than one fifth of patients. We suggest that the high prevalence of ACEi and ARB usage in patients with type 2 DN may be effecting the traditional clinical paradigm of type 2 DN.

Keywords:
Type 2 diabetes, Proteinuria, Renal impairment, Renin-angiotensin system inhibition
1.
Ritz E, Orth S: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127–1133.
2.
ADA: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;25(suppl 1):S33–S49.
3.
Collins AJ, Kasiske B, Herzog C, Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, Grimm R, Liu J, Louis T, Manning W, Matas A, McBean M, Murray A, St Peter W, Xue J, Fan Q, Guo H, Li S, Li S, Roberts T, Snyder J, Solid C, Wang C, Weinhandl E, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Johnson R, Sheets D, Forrest B, Berrini D, Constantini E, Everson S, Frederick P, Eggers P, Agodoa L, United States Renal Data System: Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2005;45:A5–A7.
4.
Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004:27:1047–1053.
5.
Gall MA, Nielsen FS, Smitz UM, Parving HH: The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993;36:1071–1078.
6.
Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P: Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:1051–1056.
7.
Vora JP, Dolben J, Dean JD, Thomas D, Williams JD, Owens DR, Peters JR: Renal haemodynamics in newly presenting non-insulin-dependent diabetes mellitus. Kidney Int 1992;41:829–835.
8.
Vora JP, Dolben J, Williams JD, Peters JR, Owens DR: Impact of initial treatment on renal function in newly diagnosed type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993;36:734–740.
9.
Vedel P, Obel J, Bang LE, Bang LE, Svendsen TL, Pedersen OB, Parving HH: Glomerular hyperfiltration in microalbuminuric NIDDM patients. Diabetologia 1996;39:1584–1589.
10.
Rudberg S, Osterby R: Decreasing glomerular filtration rate – an indicator of more advanced diabetic glomerulopathy in the early course of microalbuminuria in IDDM adolescents. Nephrol Dial Transplant 1997;12:1149–1154.
11.
Nosadini R, Velussi M, Brocco F, Bruseghin M, Abaterusso C, Saller A, Dalla Vestra M, Carraro A, Bortoloso E, Sambataro M, Barzon I, Frigato F, Muollo B, Chiesura-Corona M, Pacini G, Baggio B, Piarulli F, Sfriso A, Fioretto P: Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000;49:476–484.
12.
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–232.
13.
Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(suppl 2):64–78.
14.
Mogensen CE: How to protect the kidney in diabetic patients with special reference to IDDM. Diabetes 1997;46(suppl 2):104–111.
15.
Ismail N, Becker B, Strzelczyk P, Ritz E: Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kid Int 1999;55:1–28.
16.
Parving HH, Mauer M, Ritz E: Diabetic nephropathy; in Brenner B (ed): Brenner and Rector’s The Kidney, ed 8. Philadelphia, Saunders, 2007, vol 2, pp 1265–1298.
17.
Velussi M, Brocco E, Frigato F Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on renal function in hypertensive NIDDM patients. Diabetes 1996;45:216–222.
18.
Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, Jerums G: Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994;43:649–655.
19.
MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G: Non-albuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004;27:195–200.
20.
Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, Combe C, Gin H: Normoalbuminuric renal insufficient diabetic patients: a lower risk group. Diabetes Care 2007;30:2034–2039.
21.
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group: Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 2006;55:1832–1839.
22.
Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM: Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002;61:2165–2175.
23.
Kramer HJ, Nguyen QD, Curhan G, Hsu CY: Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273–3277.
24.
Perkins B, Ficociello L, Roshan B, Warram JH, Krolewski AS: In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2001;77:57–64.
25.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.
26.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
27.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
28.
De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy – lesson from RENAAL. Kidney Int 2004;65:2309–2320.
29.
Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, DeFerrari G, Drury P, Locatelli F, Wiegmann TB, Lewis EJ: Proteinuria and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281–287.
30.
American Diabetes Association: Standards of medical care in diabetes 2009. Diabetes Care 2009;32(supp 1):513–552.
31.
Levey AS, Bosch JB, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine. A new prediction equation. Ann Intern Med 1999;130:461–470.
32.
Lambers Heerspink HJ, Fowler MJ, Volgi J, Reutens AT, Klein I, Herskovits TA, Packham DK, Fraser IR, Schwartz SL, Abaterusso C, Lewis J, Collaborative Study Group: Rationale for and study design of the sulodexide trials in type 2 diabetic hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med 2007;24:1290–1295.
33.
Olson J: Diabetes mellitus; in Jenette JC, Olson JL, Schwartz MM, Silva FG (eds): Hepinstall’s Pathology of the Kidney, ed 5. Philadelphia, Lippincott-Raven, 1998, pp 1247–1286.
34.
Rychlik I, Fliser D, Ritz E: Non-diabetic renal disease in type 2 diabetes mellitus; in Ritz E, Rychlik I (eds): Nephropathy in Type 2 Diabetes. Oxford, Oxford University Press, 1999, pp 7–88.
35.
Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992;41:758–762.
36.
Gambara V, Mecca G, Remuzzi G, Bertani T: Heterogeneous nature of renal lesions in type 2 diabetes. J Am Soc Nephrol 1993;3:1458–1466.
37.
Amoah E, Glickman JL, Malchoff CD, Sturgill BC, Kaiser DL, Bolton WK: Clinical identification of non-diabetic renal disease in diabetic patients with type 1 and type 2 disease presenting with renal dysfunction. Am J Nephrol 1988;8:204–211.
38.
Waldherr R, Ilkenhans C, Ritz E: How frequent is glomerulonephritis in diabetes mellitus type 2? Clin Nephrol 1992;37:271–273.
39.
Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D, and the Collaborative Study Group: Renal pathology patterns in type 2 diabetes mellitus: relationship with retinopathy. Nephrol Dial Transplant 1998;13:2547–2552.
40.
MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H, Matthews PG, Thomas MC, Power DA, Jerums G: Is non-albuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006;29:1560–1566.
41.
Onuigbo MA, Onuigbo NT: Use of ultrahigh RAAS blockade: implications for exacerbation of renal failure. Kidney Int 2006;69:194–195.
42.
Onuigbo MA, Onuigbo NT: Late onset renal failure from RAAS blockade. Kidney Int 2006;70:1378–1379.
43.
Kasiske BL, Kalil RS, Maj Z, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta regression analysis. Ann Intern Med 1993;118:129–138.
44.
Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE Collaborative Group: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813–1821.
45.
Halbesma N, Kuiken DS, Brantsma AH, Bakker SJ, Wetsels JF, De Zeeuw D, De Jong PE, Gansevoort RT: Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006;17:2582–2590.
46.
Ahmed AK, Kamath NS, El Kossi M, El Nahas M: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010;25:3977–3982.
47.
Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG, University of Toronto Acute Kidney Injury Research Group: Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009;302:1179–1185.
48.
Ishani A, Xue J, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ: Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009;20:223–228.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.